Abstract
Maintenance of medically induced remission is a clinical challenge in Crohn's disease (CD), since it is a chronic disease and that often occurs in young people. The introduction of immunosuppressors and biologics has significantly improved the management of these patients, however efficacy and safety of these treatments in the very long term still needs clarification. Furthermore, scientific research is driven more into new drugs to induce remission rather then maintenance.
MeSH terms
-
Adalimumab
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Inflammatory Agents / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Budesonide / therapeutic use
-
Crohn Disease / diet therapy
-
Crohn Disease / drug therapy*
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Infliximab
-
Methotrexate / therapeutic use
-
Randomized Controlled Trials as Topic
-
Remission Induction
-
Salicylates / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunosuppressive Agents
-
Salicylates
-
Budesonide
-
Infliximab
-
Adalimumab
-
Methotrexate